Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later
✍ Scribed by H. Briem; A. Safary
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 288 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
An inactivated vaccine against hepatitis A was administered as a single 1,440 enzyme‐linked immunosorbent assay (ELISA) units dose at month 0 with a booster at month 6 to 200 subjects divided into two age groups: group 1, 20–39 years (n = 134) and group II, 40–62 years (n = 66). At day 15, the seropositivity rates were 90% and 77% in groups I and II, respectively. At month 1 the seropositivity rate was 97% in both groups. At month 6 the seropositivity rates were 94% and 88% in groups I and II, respectively. One month after the booster, at month 7, 100% in both groups had become seropositive. The vaccine was well tolerated and did not cause any severe reactions. The results indicate that a single high vaccine dose offers protection against hepatitis A virus (HAV) for at least 6 months in the majority of cases where rapid vaccination is required even in travellers of older age. A booster dose will ensure long‐term protection. © 1994 Wiley‐Liss, Inc.